Educational Tools

GuidelineStat™
Managing Non-Small Cell Lung Cancer in the Clinical Setting

GuidelineStat™ Managing Non-Small Cell Lung Cancer in the Clinical Setting is a CME initiative developed in conjunction with a leading expert from the Abramson Cancer Center at the University of Pennsylvania that provides evidence-based guideline content for the treatment and management of non-small cell lung cancer.

This learning activity has been designated for a maximum of 1.50 AMA PRA Category 1 Credits™.

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

After reviewing this module, the participant will be better able to:
  • State the appropriate course of action for patients with stage II-III NSCLC with positive margins versus negative margins following surgical resection
  • Explain recommended first-line adjuvant therapy for stage II-III NSCLC
  • Discuss the major controversy relating to the sequence of treatment modalities for patients with stage IIIA disease

View all Learning Objectives.

Content Highlights
Lung cancer is the leading cause of cancer death in the United States (and worldwide) and non-small cell histology accounts for over 85% of all lung cancer cases. Late diagnosis can impede survival outcomes, but favorable clinical prognostic factors generally include good performance status, no weight loss, and female gender.

Please register to learn more



Editorial Faculty
Corey J. Langer, MD, FACP
Professor of Medicine
University of Pennsylvania
Director of Thoracic Oncology
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA
This educational activity was made possible through an unrestricted educational grant from:
Developed and published in 2009 by Mechanisms in Medicine Inc. Copyright © Mechanisms in Medicine Inc. and Imedex, LLC. All rights reserved.
About Us | Contact Us | Terms of Use | Privacy Policy | Technical Requirements | Site Map | Help